Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Kupfer

Showing results (31-40 of 99) with videos related to

Pageof 10
Sort By:
Annals of Internal Medicine|June 21, 2006
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?Franz H Messerli, Giuseppe Mancia, C Richard Conti, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 27, 2025
Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trialStacy A Rudnicki, Paulos Gebrehiwet, Stuart Kupfer, et al.
Journal of the American College of Cardiology|January 8, 2011
Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) studyStephen J Nicholls, E Murat Tuzcu, Kathy Wolski, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|May 12, 2017
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertensionWallace Johnson, William B White, Domenic Sica, et al.
Thrombosis and Haemostasis|March 28, 2014
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndromeSidney Goldstein, Eric R Bates, Deepak L Bhatt, et al.
Heart Failure Reviews|April 21, 2015
Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulationsMuthiah Vaduganathan, Javed Butler, Lothar Roessig, et al.
Thrombosis and Haemostasis|January 17, 2003
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiologyJacqueline A Brassard, Brian R Curtis, Richard A Cooper, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 18, 2018
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 DiabetesKatherine G Garlo, William B White, George L Bakris, et al.
Heart Failure Clinics|July 2, 2013
Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectivesMihai Gheorghiade, Ami N Shah, Muthiah Vaduganathan, et al.
Clinical and Translational Science|March 5, 2026
Clinical Evaluation of Drug-Drug Interactions With AficamtenNeha Maharao, Donghong Xu, Punag Divanji, et al.
Pageof 10

Showing results (31-40 of 99) with videos related to

Sort By:
Pageof 10
Annals of Internal Medicine|June 21, 2006
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?Franz H Messerli, Giuseppe Mancia, C Richard Conti, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 27, 2025
Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trialStacy A Rudnicki, Paulos Gebrehiwet, Stuart Kupfer, et al.
Journal of the American College of Cardiology|January 8, 2011
Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) studyStephen J Nicholls, E Murat Tuzcu, Kathy Wolski, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|May 12, 2017
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertensionWallace Johnson, William B White, Domenic Sica, et al.
Thrombosis and Haemostasis|March 28, 2014
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndromeSidney Goldstein, Eric R Bates, Deepak L Bhatt, et al.
Heart Failure Reviews|April 21, 2015
Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulationsMuthiah Vaduganathan, Javed Butler, Lothar Roessig, et al.
Thrombosis and Haemostasis|January 17, 2003
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiologyJacqueline A Brassard, Brian R Curtis, Richard A Cooper, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 18, 2018
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 DiabetesKatherine G Garlo, William B White, George L Bakris, et al.
Heart Failure Clinics|July 2, 2013
Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectivesMihai Gheorghiade, Ami N Shah, Muthiah Vaduganathan, et al.
Clinical and Translational Science|March 5, 2026
Clinical Evaluation of Drug-Drug Interactions With AficamtenNeha Maharao, Donghong Xu, Punag Divanji, et al.
Pageof 10